Arterial indications for the low molecular weight heparins

Table 4 Randomized trials of low molecular weight heparin (LMWH) in unstable angina and non-Q-wave myocardial infarction (MI)

				Treatment
				duration	Follow-up	LMWH	Control
Study	LMWH	n	Primary outcome	(days)	(days)	(%)	(%)	P
Gurfinkel et al,	n	211	MI, death, recurrent angina, urgent	5–7	5–7	22	59^*	0.00001
1995 [19]			revascularization, major bleeding				63^†	0.00001
FRISC, 1996 [20]	Dalteparin	1506	MI – death	35–45	6	1.8	4.8^‡	0.001
					40	8.0	10.7^‡	0.07
					150	14	15.5^‡	0.41
FRIC, 1997 [23]	Dalteparin	1506	MI/death/recurrent angina	6	6	9.3	7.6^†	0.33
				45	6–45	12.3	12.3^‡	0.96
ESSENCE, 1997 [24]	Enoxaparin	3171	MI/death/recurrent angina	2–8	14	16.6	19.8^†	0.02
					30	19.8	23.3^†	0.02
						6/14 days
FRAXIS, 1999 [28]	Nadroparin	3468	MI/death/refractory angina	6 or 14	6	13.8/15.8	14.9^†	ns
					14	17.8/20.0	18.1^†	ns
					90	22.3/25.2	22.2^†	ns
FRISC II, 1999 [26]	Dalteparin	2267	Death – MI	90	30	3.1	5.9^‡	0.002
					90	6.7	8.0^‡	0.17
TIMI 11b, 1999 [27]	Enoxaparin	3910	Death/MI/urgent revascularization	8 or 43	14	14.2	16.6^†	0.03
					43	17.3	19.6^†	0.049

ISSN: 1745-6215